Cargando…
811. A Randomized Controlled Trial of Prednisolone vs. Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Lepra Reaction in Leprosy Patients
BACKGROUND: Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae. Type 1 lepra reactions (T1R) are delayed hypersensitivity (Type IV) reactions which if not treated promptly leads to disability affecting eyes, hands and feet. IL-17 A which is produced mainly by inflam...
Autor principal: | Mitra, Debdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254982/ http://dx.doi.org/10.1093/ofid/ofy210.818 |
Ejemplares similares
-
1356. A Randomized Controlled Trial of Prednisolone vs. TNF-α inhibitor Infliximab in the Management of Type 1 Lepra Reaction in Leprosy Patients
por: Chopra, Ajay, et al.
Publicado: (2019) -
A Randomized Controlled Trial of Anti-TNF α Bio-similar Adalimumab vs. Prednisolone in the Management of Leprosy Patients with New Type 1 Lepra Reaction
por: Mitra, Debdeep
Publicado: (2017) -
Rare Atypical Presentations in Type 2 Lepra Reaction: A Case Series
por: Mitra, Debdeep
Publicado: (2017) -
1345. Randomized Control Trial to Evaluate the Clinical and Cytokine Response Profile to Oral Thalidomide in Leprosy Patients with Erythema Nodosum Leprosum
por: Chopra, Ajay, et al.
Publicado: (2019) -
Type I Lepra Reaction as the Presenting Sign of Histoid Leprosy
por: Sun, Jingru, et al.
Publicado: (2017)